Fresenius

Fresenius Medical Care AG & Co. KGaA provides kidney dialysis services through a network of 3,900 outpatient dialysis centers, serving 336,000 patients. The company primarily treats end-stage renal disease, which requires patients to undergo dialysis 3 times per week for the rest of their lives.

Fresenius SE & Co. KGaA engages in the provision of healthcare related products and services. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed, and Corporate and Other. The Fresenius Medical Care segment provides dialysis products and services. The Fresenius Kabi segment specializes in intravenously administered generic drugs, clinical nutrition, and infusion therapies. The Fresenius Helios segment operates acute and maximum care hospitals as well as post-acute care clinics. The Fresenius Vamed segment manages projects and offers services for hospitals and other healthcare facilities. The Corporate and Other segment comprises the holding activities of the company and the information technology service provider Fresenius Netcare. The company was founded by Eduard Fresenius in October 1912 and is headquartered in Bad Homburg, Germany.